TORRANCE, Calif. and IRVINE, Calif., Sept. 27, 2012 /PRNewswire/ -- Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, and ChromaDex® Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today a collaboration agreement that will provide solutions to customers with a combination of reference standards, scientifically valid methods and application support. The collaboration combines Phenomenex's strengths in analytical HPLC (high-performance liquid chromatography) with ChromaDex's extensive line of reference standards, which are used for quality control in dietary supplement manufacturing. The first three new solutions will be presented as scientific posters at the AOAC (Association of Analytical Communities) annual meeting in Las Vegas next week and will be available as technical notes, the first of which can be viewed at www.phenomenex.com/cdpr.
The FDA has increased its scrutiny of the supplement industry in recent years, precipitating a need for faster, more advanced quality control methods. "The ability to provide a complete package of reference standards and scientifically valid methods strengthens our leadership position and provides a 'one-stop shop' for our customers," said Frank Jaksch, CEO and founder of ChromaDex. "The collaboration will deliver tools to help customers meet FDA guidance on cGMP (current good manufacturing practices) for dietary supplements."
Phenomenex maintains a full-service analytical support laboratory, staffed with application scientists who specialize in method development and customized solutions. This team will optimize methods for ChromaDex reference standards, based on the most advanced chromatography technology. This includes working with a variety of sample matrices and will in many cases include the use of Phenomenex's core-shell particle technology and Kinetex® columns.
"This collaboration is consistent with our strategy of providing the most complete solutions to the customers we serve," explains Sky Countryman, manager of PhenoLogix and applied technology for Phenomenex. "We look forward to expanding our involvement with the growing dietary supplement market."
ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. ChromaDex's pipeline of proprietary products include patented pTeroPure® pterostilbene, which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan. The company has also launched ProC3G™, a natural black rice extract containing 40% cyanidin-3-glucoside and is in the process of developing Nicotinamide Riboside, a novel next-generation B-vitamin. All products are backed with extensive scientific research and intellectual property. For more information about pTeroPure, visit www.pteropure.com or call 949-600-9694.
Phenomenex, celebrating its 30th anniversary in 2012, is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in industrial, clinical, government and academic laboratories. From drug discovery and pharmaceutical development to disease diagnosis, food safety and environmental analysis, Phenomenex chromatography solutions accelerate science and help researchers improve global health and well-being. For more information on Phenomenex, visit www.phenomenex.com or follow the company on Twitter @Phenomenex.
Please send READER INQUIRIES from this news release directly to: email@example.com
Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies' filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
Contacts for the Media:
Jennifer Dahlgren, Dahlgren Communications
Phone: (530) 265-0538
Karen Anspach, Phenomenex, Inc.
Phone: (310) 212-0555 Ext. 2243
ChromaDex Investor Contact:
The Del Mar Consulting Group, Inc.
Robert B. Prag, President
Laura Carney, Executive Assistant
SOURCE Phenomenex Inc.; ChromaDex Corporation